Copaxone is another name for glatiramer acetate Multiple Sclerosis which is given in a daily injection under the skin. It has been found to be one of the most effective meds available to help extend the time between relapses in those who have relapsing-remitting MS (RRMS). The US Food and Drug Administration (FDA) has not yet designated the drug as a treatment to prevent the progression of MS.

Glatiramer acetate MS was first approved by the FDA in 1996 and since that time has shown to not only prevent relapses, but also to have reduced the number of lesions shown on the MRI’s of the patients taking it. It has also become a first-line treatment for those that have experienced a Clinically Isolated Syndrome (CIS) or the first appearance of neurological symptoms that may indicate the possibility of MS developing.

In February 2010, a 15-year clinical study was published showing …

Glatiramer Acetate Multiple Sclerosis treatment has shown promise in treating patients who have the relapsing-remitting form of the disease.  Glatiramer Acetate MS also seems to be well tolerated and is shown to maintain its positive clinical effects on relapse rates over the longer term.  So far the really good results have been with the relapsing-remitting form of MS.  Those with other forms have not shown similar results to date.

Glatiramer, going under the brand name Copaxone, is an artificial protein that bears close resemblance to the natural myelin protein.  This is another case of not knowing exactly how the medicine works, but Glatiramer Acetate Multiple Sclerosis treatment has shown signs of slowing the disease’s progression or even extending the time before you actually get the disease when treatment begins after a single episode of a neurological symptom like optic neuritis for example.  It needs to be repeated that the best …